Polaryx Therapeutics Inc. Common Stock

PLYX | NASDAQ

$1.74

-$0.01 (-0.57%)

Nov 2, 2026, 2:11 PM ET · Market open

Fiscal Quarter Period Ending	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024
Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-1.38M	-1.96M	-911K	-974K	-884K	-5.05M	-723K	-771K
Interest Income	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pretax Income	-1.38M	-2.54M	-1.5M	-1.43M	-1.01M	-5.05M	-723K	-771K
Net Income	-1.38M	-2.54M	-1.5M	-1.43M	-1.01M	-5.05M	-723K	-771K
Selling & General & Admin	661K	1.28M	351K	460K	408K	336K	373K	417K
Research & Development	719K	679K	560K	514K	476K	4.72M	350K	354K
Other Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Expenses	1.38M	1.96M	911K	974K	884K	5.05M	723K	771K
Interest Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	1.38M	1.96M	911K	974K	884K	5.05M	723K	771K
Income Tax Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	48.28M	47.22M	47.34M	189.37M	189.37M	189.37M	189.37M	189.37M
Shares Outstanding (Diluted)	48.28M	47.22M	47.34M	189.37M	189.37M	189.37M	189.37M	189.37M
EPS (Basic)	-0.03	-0.05	-0.03	-0.01	-0.01	-0.03	0	0
EPS (Diluted)	-0.03	-0.05	-0.03	-0.01	-0.01	-0.03	0	0
EBITDA	-1.38M	-2.54M	-1.5M	-1.43M	-1.01M	-5.05M	-723K	-771K
EBIT	-1.38M	-2.54M	-1.5M	-1.43M	-1.01M	-5.05M	-723K	-771K
Depreciation & Amortization	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a